Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
7.15 USD +0.42% Intraday chart for Candel Therapeutics, Inc. -19.66% +386.39%
May. 30 FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma MT
May. 30 Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment DJ

Evolution of the average Target Price on Candel Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3babf5dc9dd98c696c1786.Nabq5idag6miLJg601MvXURLCr65d7AWczkldeocFoQ.b-CApFcx2ubIS6115AFiZCUKQP_mDvg7IWBhI45ycu9Gyri8EWzIkOBb3Q~25df243d729c871c789042a546d16c60

Analyst Recommendations on Candel Therapeutics, Inc.

Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating MT
UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating MT
Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating MT
HC Wainwright Starts Candel Therapeutics at Buy With $11 Price Target MT
BMO Capital Adjusts Candel Therapeutics' Price Target to $12 from $18, Keeps Outperform Rating MT
BMO Initiates Candel Therapeutics With Outperform Rating, $18 Price Target MT
Candel Therapeutics : Shares Rise After Analyst Recommendations MT
CANDEL THERAPEUTICS : Credit Suisse Starts Candel Therapeutics at Outperform with $15 PT, Notes Potential for Improved Investor Sentiment, Valuation MT
CANDEL THERAPEUTICS : UBS Starts Candel Therapeutics at Buy With $9 Price Target MT
CANDEL THERAPEUTICS : Jefferies Starts Candel Therapeutics at Buy With $22 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
7.15 USD
Average target price
11 USD
Spread / Average Target
+53.85%
High Price Target
11 USD
Spread / Highest target
+53.85%
Low Price Target
11 USD
Spread / Lowest Target
+53.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Candel Therapeutics, Inc.

Credit Suisse
UBS
HC Wainwright
BMO Capital
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CADL Stock
  4. Consensus Candel Therapeutics, Inc.